CXCL9在乳腺癌中的表达及其与肿瘤免疫浸润特征的相关性研究
CXCL9 expression in breast cancer and its correlation with the characteristics of tumor immunoinfiltration
Note： A. Expression of CXCL9 mRNA in different types of tumor and their corresponding normal tissues (①P=0.050, ②P=0.010, ③P=0.001). ACC—adrenocortical carcinoma; BLCA—bladder urothelial carcinoma; BRCA—breast invasive carcinoma; CESC—cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL—cholangiocarcinoma; COAD—colon adenocarcinoma; DLBC—lymphoid neoplasm diffuse large B-cell lymphoma; ESCA—esophageal carcinoma; GBM—glioblastoma multiforme; HNSC—head and neck squamous cell carcinoma; KICH—kidney chromophobe; KIRC—kidney renal clear cell carcinoma; KIRP—kidney renal papillary cell carcinoma; LAML—acute myeloid leukemia; LGG—brain lower grade glioma; LIHC—liver hepatocellular carcinoma; LUAD—lung adenocarcinoma; LUSC—lung squamous cell carcinoma; MESO—mesothelioma; OV—ovarian serous cystadenocarcinoma; PAAD—pancreatic adenocarcinoma; PCPG—pheochromocytoma and paraganglioma; PRAD—prostate adenocarcinoma; READ—rectum adenocarcinoma; SARC—sarcoma; SKCM—skin cutaneous melanoma; STAD—stomach adenocarcinoma; TGCT—testicular germ cell tumor; THCA—thyroid carcinoma; THYM—thymoma; UCEC—uterine corpus endometrial carcinoma; UCS—uterine carcinosarcoma; UVM—uveal melanoma. B. Boxplot of CXCL9 mRNA expression in four molecular types of breast cancer and adjacent tissues. C/D. Observation (C) and statistical analysis (D) of differential expression of CXCL9 in breast cancer tissues and adjacent tissues by IHC. E. Detection of the effect of CXCL9 mRNA expression on prognosis of breast cancer patients by KM survival curve.
